Indices
Select Exchange
NSE
BSE
IIFL View

  • SPARC

    SPARC is awaiting USFDA approval on its late stage innovative drugs, Elepsia (Epilepsy drug) and Xelpros (Glaucoma drug). Both ...

    Accumulate Reco. Price: 383.95

  • Narayana Hrudaya

    Company operates an asset light model with lowest capital cost per operational bed than peers (Rs28lakh per bed in Q2FY18). We ...

    Accumulate Reco. Price: 244.60

Equity News
FII & DII Activity
Select Activity
FII Equity
DII Equity
Depository Receipt
Videos
Sectoral Newsletter
Sector Performance
Corporate Actions

Displaying Events for 14th Jul - 14th Aug 2018

Bulk & Block
Select Deal
Bulk
Block